© 2003 by Oxford University Press
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
© 2003 Oxford University Press
NEWS |
Big Plans for Small Molecules: NIH Launches Chemical Genomics Initiative
| The first 10% of the full text of this article appears below. |
The National Institutes of Health, as part of its new "Roadmap for Medical Research," is launching a major chemical genomics initiative. Directors of almost every institute within NIH gathered in late September to announce plans for the Roadmap, a special program to speed the transition of basic research to medical advances (see box p. 1741). Little attention was given to the chemical genomics initiative, spearheaded by the National Human Genome Research Institute (NHGRI), but it represents a major commitment to a new approach to public sector drug discovery.
Chemical genomics is "the broad-based use of small molecule, drug-like compounds to study the biological function and therapeutic potential of the genome," in the words of Chris Austin, M.D., senior adviser to NHGRI director Francis Collins, M.D., Ph.D. (Collins, in papers, lectures, and interviews, has
Related News Article in JNCI
![]()
CiteULike
Connotea
Del.icio.us What's this?
J Natl Cancer Inst 2003 95: 1741.